📰 Mark Bleackley News
Page 3 - Mark Bleackley News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Bleackley. Real-time updates on events, politics, business and more.
February 27, 2023
Medicinal cannabinoid and psychedelic therapies developer Incannex Healthcare (ASX: IHL) has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis.
January 18, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has achieved an interim milestone for the PsiGAD1 clinical trial assessing the effect of psilocybin-assisted...
November 29, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to...
November 28, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to...
November 25, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged Eurofins Scientific, a multinational contract development and manufacturing organisation, to...
October 13, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has completed the dosing stage in its Phase 1 anti-inflammatory drug trial. The early-stage study is...
October 11, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has presented its pre-Investigational New Drug Application (pre-IND) for traumatic brain injury and...
September 9, 2022
Dronabinol shows promise for the treatment of sleep apnea, and new advances from pharmaceutical companies show how it can be optimized.
September 8, 2022
Dronabinol shows promise for the treatment of sleep apnea, and new advances from pharmaceutical companies show how it can be optimized.
August 2, 2022
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged leading contract research, development and manufacturing company Curia Global Inc to develop and...